GenSight Biologics (SIGHT) H1 2024 earnings summary

Executive summary

• Achieved a 60% reduction in cash outflow compared to the same period in 2023 through financial discipline and renegotiation of obligations.

• Cash runway extended to mid-November 2024, with potential to Q3 2025 if the Early Access (AAC) Program resumes as expected.

• LUMEVOQⓇ drug product batch expected to be released for human use in mid-October 2024, with proceeds from AAC restart anticipated from November 2024.

• Appointed Jan Eryk Umiastowski as Chief Financial Officer, bringing over 26 years of finance and M&A experience.

Financial highlights

• Operating income decreased by 36.4% to €1.7M from €2.7M year-over-year.

• Net loss reduced to €5.8M in H1 2024 from €12.0M in H1 2023; EPS improved to €(0.07) from €(0.26).

• Net cash flows from operating activities improved to €(7.3)M from €(16.2)M year-over-year.

• Cash and cash equivalents at June 30, 2024, were €6.9M, up from €1.0M a year earlier.

• Financing activities generated €12.1M in H1 2024, up from €6.4M in H1 2023, due to capital increases and share warrant exercises.

Outlook and guidance

• Cash runway extends to mid-November 2024, with potential extension to Q3 2025 if AAC resumes and generates expected proceeds.

• If AAC program is delayed, temporary financing such as receivables sales may be needed; otherwise, refinancing required before mid-November 2024.

• Plans to pursue additional financing, partnerships, or M&A to support ongoing activities and new clinical trials.